{"id":39699,"date":"2022-01-19T04:28:16","date_gmt":"2022-01-19T04:28:16","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=39699"},"modified":"2026-05-05T16:05:51","modified_gmt":"2026-05-05T20:05:51","slug":"pesquisa-de-mercado-genetica","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/pt\/solucoes\/inovacao\/pesquisa-de-mercado-genetica\/","title":{"rendered":"Genetics Market Research: Commercial Strategy"},"content":{"rendered":"
\n

Pesquisa de mercado de gen\u00e9tica<\/h1>\n
\"Pesquisa<\/figure>\n<\/p>\n

O que \u00e9 gen\u00e9tica?<\/h2>\n

A gen\u00e9tica \u00e9 uma \u00e1rea da biologia que estuda todas as formas de vida. Inclui o DNA, como os genes se formam e como as plantas e os animais herdam esses genes. Analisa como os organismos transmitem genes e caracter\u00edsticas de uma gera\u00e7\u00e3o para outra. Os dados transportados pelos genes afetam a sa\u00fade e a apar\u00eancia de uma pessoa. Afeta at\u00e9 a personalidade!<\/p>\n<\/div>\n

Genetics Market Research: How Leading Firms Convert Scientific Complexity into Commercial Advantage<\/h1>\n

Genetics market research sits at the intersection of laboratory science, consumer psychology, payer economics, and regulatory strategy. Few categories punish generic methodology more harshly. The companies winning in this space share a discipline: they design research that respects the scientific substrate while reading the commercial signal underneath it.<\/p>\n

The opportunity is widening. Direct-to-consumer testing, hereditary cancer panels, pharmacogenomics, carrier screening, liquid biopsy, and polygenic risk scoring now compete for clinician attention, payer reimbursement, and patient wallet share simultaneously. Each audience evaluates the same assay through a different lens. Research that collapses these lenses into one survey produces noise. Research that separates them produces strategy.<\/p>\n

Why Genetics Market Research Demands a Different Operating Model<\/h2>\n

Conventional life sciences research treats the genetics buyer as a single decision unit. The buyer is not. A hereditary cancer panel moves through a genetic counselor, an ordering oncologist, a hospital lab director, a managed care medical director, and the patient. Each holds veto power. Each weighs different evidence.<\/p>\n

The leading commercial teams build segmented evidence stacks. Clinical utility data persuades the oncologist. Analytical validity data persuades the lab director. Health economic modeling persuades the payer. Turnaround time and report clarity persuade the counselor. Cost and emotional framing persuade the patient. Genetics market research that maps these proof requirements separately, then tests messaging against each, outperforms research that averages them.<\/p>\n

De acordo com A SIS International Research<\/a>, the genetics product categories that achieved durable adoption shared one structural feature: their commercial teams invested in qualitative discovery with genetic counselors before quantifying clinician demand.<\/span> Counselors function as the gatekeeping channel and the interpretive layer, and their objections predict ordering behavior more reliably than physician stated preference.<\/span><\/p>\n

The Five Audiences Inside Every Genetics Launch<\/h2>\n

Treat the genetics buyer as a five-node network. Each node requires distinct primary research design.<\/p>\n

\n\n\n\n\n\n\n\n\n\n
Audience<\/th>\nDecision Driver<\/th>\nPreferred Research Method<\/th>\n<\/tr>\n<\/thead>\n
Ordering Clinician<\/td>\nClinical utility, guideline alignment<\/td>\nB2B expert interviews, conjoint analysis<\/td>\n<\/tr>\n
Genetic Counselor<\/td>\nReport interpretability, variant classification<\/td>\nEthnographic observation, focus groups<\/td>\n<\/tr>\n
Lab Director<\/td>\nAnalytical validity, throughput, integration<\/td>\nTechnical deep-dive interviews<\/td>\n<\/tr>\n
Payer Medical Director<\/td>\nCost-effectiveness, coverage policy fit<\/td>\nStructured payer panels, dossier testing<\/td>\n<\/tr>\n
Patient or Consumer<\/td>\nTrust, privacy, emotional framing<\/td>\nCLTs, journey mapping, concept testing<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

Aggregating these audiences into a single quantitative instrument suppresses the very signals that determine launch success. A counselor’s frustration with variant of uncertain significance reporting will not surface in a physician panel. A payer’s stance on prior authorization will not surface in patient surveys. The model requires parallel tracks, not a single track.<\/p>\n

What Direct-to-Consumer Genetics Taught the Clinical Market<\/h2>\n

The trajectories of 23andMe, AncestryDNA, MyHeritage, and Color Health offer the clearest commercial lesson in the category. Consumer testing scaled when it solved for emotional payoff first and clinical accuracy second. Clinical genetics scales when it inverts that order. The companies that confused the two paths underperformed.<\/p>\n

SIS International’s qualitative work in consumer genetics, including focus groups and structured concept testing on sample kits, reports, and channel preferences, surfaced a consistent finding: purchase intent correlates more strongly with perceived report clarity than with clinical depth. Buyers reward legibility. Companies that overinvested in scientific density without investing in narrative design saw lower conversion across direct channels.<\/span><\/p>\n

This pattern carries into clinical settings. Ordering physicians describe report fatigue when interpreting multi-gene panels. The commercially superior product is rarely the one with the most variants tested. It is the one with the cleanest decision pathway embedded in the report.<\/p>\n

The Reimbursement Gate Determines Commercial Velocity<\/h2>\n

Coverage is the variable that separates promising assays from commercial winners. CMS coverage decisions, MolDX policy, and commercial payer alignment compress or expand a launch curve more than any messaging campaign. Research programs that delay payer engagement until post-launch consistently underperform.<\/p>\n

The stronger approach treats payer evidence requirements as a research input from day one. Structured interviews with medical directors at national and regional plans surface the cost-effectiveness thresholds, comparator expectations, and real-world evidence formats that will govern coverage. Pharmacogenomics products from companies like Myriad Genetics and Natera advanced when their evidence packages anticipated payer questions rather than reacted to them.<\/p>\n

The SIS Genetics Commercialization Lens<\/h2>\n

Across genetics engagements, the firms that translate science into share gain operate on a four-quadrant lens.<\/p>\n